Provided by Tiger Trade Technology Pte. Ltd.

HUTCHMED

19.770
+0.0100.05%
Volume:3.31M
Turnover:65.16M
Market Cap:17.24B
PE:4.85
High:20.080
Open:20.080
Low:19.420
Close:19.760
52wk High:28.800
52wk Low:15.570
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:0.47
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(LYR):4.077
ROE:1.46%
ROA:-1.24%
PB:1.74
PE(LYR):4.85
PS:4.00

Loading ...

Dow Jones Top Company Headlines at 1 PM ET: Walmart Shares Slump on Weakest Sales Growth in over Six Years | Super ...

Dow Jones
·
Aug 21

Dow Jones Top Company Headlines at 7 am ET: Alibaba Posts Weaker Earnings Amid Heavy AI Investments | Deere's ...

Dow Jones
·
Aug 20

Hutchmed (China) Ltd: Insolvency Proceedings Remain Ongoing, Outcome of Proceedings is not Known to Company as at Date of This Announcement

THOMSON REUTERS
·
Aug 18

Hutchmed (China) - S.d. Sight Diagnostics Subject to Insolvency Proceedings in Israel

THOMSON REUTERS
·
Aug 18

Hutchmed (China) - Amount Involved in Insolvency Proceedings is Nis3,057,876 (us$1,019,292)

THOMSON REUTERS
·
Aug 18

CICC Adjusts HUTCHMED Outlook, Lifting Price Target to HK$26 on Strong Trial Results

Stock News
·
Aug 18

HUTCHMED Surges Nearly 4% on Positive Late-Stage Trial Results for Combination Therapy

Stock News
·
Aug 17

Hong Kong Stocks Rise on Monday on Tech Gains; Alibaba Rises 2%

MT Newswires Live
·
Aug 17

HUTCHMED Stock Surges on Positive Drug Trial Results for Lung Cancer Therapy Combination

Deep News
·
Aug 17

HK's Hutchmed Rises on Progress of Orpathys Plus Tagrisso for Cancer Treatment

Reuters
·
Aug 17

HK Movers | Pharma Stocks Gain With HUTCHMED up 8%, JOINN up 6%

Tiger Newspress
·
Aug 17

HUTCHMED: ORPATHYS®-TAGRISSO® Combo Delivers Significant PFS and OS Gains in Global Phase III SAFFRON Study for MET-Driven EGFR-Mutant NSCLC

Bulletin Express
·
Aug 17

Hutchmed (China) - Says Orpathys Plus Tagrisso Improves Survival in Egfr-Mutated Nsclc in Phase Iii Trial

THOMSON REUTERS
·
Aug 17

Hutchmed Says Savolitinib Plus AstraZeneca’s Tagrisso Lifts PFS and OS in Phase III Lung Cancer Trial

Reuters
·
Aug 17

Hutchmed Announces Orpathys® Plus Tagrisso® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in Met-Driven Egfr-Mutated Lung Cancer After Progression on Tagrisso®

THOMSON REUTERS
·
Aug 17

HUTCHMED H1 2026: Net Profit at $15.90 Million, Oncology Revenue Climbs 23%, Liquidity Reaches $1.37 Billion

Bulletin Express
·
Aug 14

Hutchmed H1 FY26 Net Income Drops to $15.9 Million; Revenue Rises 0.22% to $278.3 Million

Reuters
·
Aug 14

UBS Adjusts HUTCHMED Target Price to HK$29.5, Maintains Buy Rating

Stock News
·
Aug 03

Hutchmed H1 FY26 Net Income Drops to USD 15.9 Million; Revenue Rises 0.22% to USD 278.3 Million

Reuters
·
Jul 30

HUTCHMED (China) H1 EPS $0.09 Down From $2.61 YoY, Sales $278.287M Up From $277.677M YoY

Benzinga Earnings
·
Jul 30